HOSPITAL UNIVERSITARIO RUBER

2016

1. A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds

   Cell, Vol. 167, Núm. 1, pp. 260-274.e22

2. A prognostic neonatal neuroimaging scale for symptomatic congenital cytomegalovirus infection

   Neonatology, Vol. 110, Núm. 4, pp. 277-285

3. Adipose mesenchymal stromal cell therapy in a desperate case of right-hand ischemia

   Cytotherapy, Vol. 18, Núm. 6, pp. 725-728

4. Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel

   Annals of Oncology, Vol. 27, Núm. 3, pp. 379-390

5. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial

   The Lancet Oncology, Vol. 17, Núm. 3, pp. 357-366

6. Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension

   Basic Research in Cardiology, Vol. 111, Núm. 4

7. Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases

   Cancer and Metastasis Reviews, Vol. 35, Núm. 2, pp. 323-332

8. Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response

   Annals of Surgical Oncology, Vol. 23, Núm. 12, pp. 3831-3837

9. Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention

   Journal of the American College of Cardiology, Vol. 67, Núm. 23, pp. 2705-2715

10. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer

    Cancer Research, Vol. 76, Núm. 8, pp. 2301-2313

11. Etirinotecan pegol for the treatment of breast cancer

    Expert Opinion on Pharmacotherapy, Vol. 17, Núm. 5, pp. 727-734

12. Ex vivo high-frequency ultrasound: A novel proposal for management of surgical margins in patients with non-melanoma skin cancer

    Journal of the American Academy of Dermatology, Vol. 74, Núm. 6, pp. 1278-1280

13. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

    Annals of Oncology, Vol. 27, Núm. 11, pp. 2046-2052

14. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

    Oncotarget, Vol. 7, Núm. 35, pp. 56295-56308

15. Genetic evolution of nevus of Ota reveals clonal heterogeneity acquiring BAP1 and TP53 mutations

    Pigment Cell and Melanoma Research, Vol. 29, Núm. 2, pp. 247-253

16. Genetic profile of GNAQ-mutated blue melanocytic neoplasms reveals mutations in genes linked to genomic instability and the PI3K pathway

    Oncotarget, Vol. 7, Núm. 19, pp. 28086-28095

17. HERMIONE: A randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

    BMC Cancer, Vol. 16, Núm. 1

18. High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy

    Molecular Oncology, Vol. 10, Núm. 1, pp. 138-147

19. Impact of the Timing of Metoprolol Administration during STEMI on Infarct Size and Ventricular Function

    Journal of the American College of Cardiology, Vol. 67, Núm. 18, pp. 2093-2104

20. Leiomioma cutáneo atípico en un paciente con leiomiomatosis cutánea y mutación de la enzima fumarato hidratasa

    Investigacion Clinica (Venezuela), Vol. 57, Núm. 1, pp. 59-65